Monoclonal

Monoclonal means "from a single cell origin." In medicine, it usually refers to antibodies or cell populations that are all genetically identical because they descend from one parent cell. Monoclonal antibodies are lab-made proteins designed to bind one specific target, which makes them powerful tools for both diagnosing and treating disease.

Origin

From the Greek monos (single) and klon (twig or offshoot). The concept became central to modern medicine in 1975, when Georges Köhler and César Milstein developed hybridoma technology to mass-produce identical antibodies, work that won the 1984 Nobel Prize in Physiology or Medicine.

Significance in Asbestos Context

Monoclonal antibodies play two important roles for asbestos disease patients. First, in diagnosis: pathologists use panels of monoclonal antibodies in immunohistochemistry (IHC) staining to distinguish mesothelioma from lung cancer or metastatic tumors. Markers like calretinin, WT-1, BAP1, and MTAP are detected with these antibodies, and the results often appear in the pathology report that supports a mesothelioma diagnosis. Second, in treatment: monoclonal antibody drugs such as pembrolizumab, nivolumab, ipilimumab, and bevacizumab are now standard or emerging options for mesothelioma and asbestos-related lung cancer, working by blocking immune checkpoints or tumor blood vessel growth. The specific antibodies used to confirm your diagnosis can also matter legally, because a clear, IHC-confirmed mesothelioma diagnosis is foundational to an asbestos claim.

Example Sentence

The pathologist confirmed epithelioid mesothelioma using a panel of monoclonal antibody stains, including positive calretinin and WT-1 and loss of BAP1.

Related Terms

Immunohistochemistry, BAP1, Calretinin, Mesothelioma, Checkpoint Inhibitor, Biomarker

Notes

• Ask your oncologist or pathologist which monoclonal antibody stains were used to confirm your diagnosis; the IHC panel should be listed in your pathology report and is important documentation for both treatment planning and any legal claim.
• If you are being evaluated for immunotherapy, ask specifically about monoclonal antibody drugs targeting PD-1, PD-L1, or CTLA-4 (such as nivolumab plus ipilimumab, which is FDA-approved for unresectable pleural mesothelioma).
• Request and preserve a copy of the full pathology report, not just the summary, because the list of monoclonal markers tested supports the specificity of your diagnosis.
• Monoclonal antibody therapies can have immune-related side effects (thyroid, lung, liver, colon); report new symptoms promptly to your oncology team.